RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 A Phase 3 Trial of Biologically-Based Therapy Reduction for Intermediate Risk Neuroblastoma
JF MD Conference Express
YR 2007
FD SAGE Publications
VO 7
IS 3
SP 32
OP 34
DO 10.1177/155989770700700313
UL http://mdc.sagepub.com/content/7/3/32.abstract
AB This article reviews a phase 3 trial of biologically-based therapy reduction for intermediate risk neuroblastoma in young patients. Also discussed is a final analysis of the Head Start I and II protocols, which looked at outcome sof children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy.